» Authors » Paul R Clapham

Paul R Clapham

Explore the profile of Paul R Clapham including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 43
Citations 1223
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Verdejo-Torres O, Vargas-Pavia T, Fatima S, Clapham P, Duenas-Decamp M
J Virol . 2024 Jan; 98(1):e0152223. PMID: 38169306
Understanding how different amino acids affect the HIV-1 envelope (Env) trimer will greatly help the design and development of vaccines that induce broadly neutralizing antibodies (bnAbs). A tryptophan residue at...
2.
Quitadamo B, Peters P, Koch M, Luzuriaga K, Cheng-Mayer C, Clapham P, et al.
Arch Virol . 2018 Nov; 164(2):473-482. PMID: 30415390
Macrophage (mac)-tropic human immnunodeficiency virus type 1 (HIV-1) and simian immnunodeficiency virus (SIV) in brain are associated with neurological disease. Mac-tropic HIV-1 evolves enhanced CD4 interactions that enable macrophage infection...
3.
Brese R, Gonzalez-Perez M, Koch M, OConnell O, Luzuriaga K, Somasundaran M, et al.
J Neurovirol . 2018 Apr; 24(4):439-453. PMID: 29687407
Despite combined antiretroviral therapy (cART), HIV+ patients still develop neurological disorders, which may be due to persistent HIV infection and selective evolution in brain tissues. Single-molecule real-time (SMRT) sequencing technology...
4.
Quitadamo B, Peters P, Repik A, OConnell O, Mou Z, Koch M, et al.
J Virol . 2017 Nov; 92(2). PMID: 29118121
HIV-1 R5 variants exploit CCR5 as a coreceptor to infect both T cells and macrophages. R5 viruses that are transmitted or derived from immune tissue and peripheral blood are mainly...
5.
Gonzalez-Perez M, Peters P, OConnell O, Silva N, Harbison C, Cummings Macri S, et al.
J Virol . 2017 Aug; 91(20). PMID: 28768859
Untreated HIV-positive (HIV-1) individuals frequently suffer from HIV-associated neurocognitive disorders (HAND), with about 30% of AIDS patients suffering severe HIV-associated dementias (HADs). Antiretroviral therapy has greatly reduced the incidence of...
6.
Beauparlant D, Rusert P, Magnus C, Kadelka C, Weber J, Uhr T, et al.
PLoS Pathog . 2017 Mar; 13(3):e1006255. PMID: 28264054
A hallmark of HIV-1 infection is the continuously declining number of the virus' predominant target cells, activated CD4+ T cells. With diminishing CD4+ T cell levels, the capacity to utilize...
7.
Soto E, OConnell O, Dikengil F, Peters P, Clapham P, Ostroff G
J Drug Deliv . 2016 Dec; 2016:8520629. PMID: 27965897
Glucan particles (GPs) are hollow, porous 3-5 m microspheres derived from the cell walls of Baker's yeast ( The 1,3--glucan outer shell provides for receptor-mediated uptake by phagocytic cells expressing...
8.
Duenas-Decamp M, Jiang L, Bolon D, Clapham P
PLoS Pathog . 2016 Nov; 12(11):e1005988. PMID: 27820858
The conformation of HIV-1 envelope (Env) glycoprotein trimers is key in ensuring protection against waves of neutralizing antibodies generated during infection, while maintaining sufficient exposure of the CD4 binding site...
9.
Peters P, Gonzalez-Perez M, Musich T, Moore Simas T, Lin R, Morse A, et al.
Retrovirology . 2015 Jun; 12:48. PMID: 26055104
Background: HIV-1 variants carrying non-macrophage-tropic HIV-1 R5 envelopes (Envs) are predominantly transmitted and persist in immune tissue even in AIDS patients who have highly macrophage-tropic variants in the brain. Non-macrophage-tropic...
10.
Musich T, OConnell O, Gonzalez-Perez M, Derdeyn C, Peters P, Clapham P
Retrovirology . 2015 Mar; 12:25. PMID: 25809903
Background: Non-mac-tropic HIV-1 R5 viruses are predominantly transmitted and persist in immune tissue even in AIDS patients who carry highly mac-tropic variants in the brain. Non-mac-tropic R5 envelopes (Envs) require...